Canagliflozin, An SGLT2 Inhibitor, Prevents Lung Remodeling in Chronic Left Ventricular Failure

被引：0
|
作者：
Kanuparthy, M. [1 ]
Harris, D. D. [1 ]
Hamze, J. [1 ]
Broadwin, M. [1 ]
Stone, C. [1 ]
Banerjee, D. [1 ]
Sellke, F. W. [1 ]
机构：
[1] Brown Univ, Providence, RI USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7134
引用
收藏
页数：2
相关论文
共 50 条
  • [21] SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure
    Verma, Ashish
    Patel, Ankit B.
    Waikar, Sushrut S.
    CELL METABOLISM, 2020, 32 (01) : 13 - 14
  • [22] SGLT2 Inhibitor Use in Pediatric Heart Failure
    Butts, R.
    Nandi, D.
    Hong, B.
    Lorts, A.
    Spinner, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S479 - S479
  • [23] Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin
    Mamidi, Rao N. V. S.
    Proctor, Jim
    De Jonghe, Sandra
    Feyen, Bianca
    Moesen, Esther
    Vinken, Petra
    Ma, Jing Ying
    Bryant, Stewart
    Snook, Sandra
    Louden, Calvert
    Lammens, Godelieve
    Ways, Kirk
    Kelley, Michael F.
    Johnson, Mark D.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2014, 221 : 109 - 118
  • [24] The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    Spertus, John A.
    Birmingham, Mary C.
    Nassif, Michael
    Damaraju, C., V
    Abbate, Antonio
    Butler, Javed
    Lanfear, David E.
    Lingvay, Ildiko
    Kosiborod, Mikhail N.
    Januzzi, James L.
    NATURE MEDICINE, 2022, 28 (04) : 809 - +
  • [25] EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE
    Kolwelter, Julie
    Bosch, Agnes
    Jung, Susanne
    Linz, Peter
    Kannenkeril, Dennis
    Nagel, Armin M.
    Ott, Christian
    Bramlage, Peter
    Uder, Michael
    Achenbach, Stephan
    Schmieder, Roland
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1806 - 1806
  • [26] The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
    Ali, Amr
    Mekhaeil, Bassem
    Biziotis, Olga-Demetra
    Tsakiridis, Evangelia E.
    Ahmadi, Elham
    Wu, Jianhan
    Wang, Simon
    Singh, Kanwaldeep
    Menjolian, Gabe
    Farrell, Thomas
    Mesci, Aruz
    Liu, Stanley
    Berg, Tobias
    Bramson, Jonathan L.
    Steinberg, Gregory R.
    Tsakiridis, Theodoros
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [27] The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
    Amr Ali
    Bassem Mekhaeil
    Olga-Demetra Biziotis
    Evangelia E. Tsakiridis
    Elham Ahmadi
    Jianhan Wu
    Simon Wang
    Kanwaldeep Singh
    Gabe Menjolian
    Thomas Farrell
    Aruz Mesci
    Stanley Liu
    Tobias Berg
    Jonathan L. Bramson
    Gregory R. Steinberg
    Theodoros Tsakiridis
    Communications Biology, 6
  • [28] Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754)
    Lin, Ronghui
    Hoerr, David C.
    Weaner, Larry E.
    Salter, Rhys
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 (13): : 616 - 623
  • [29] Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans
    Kondo, H.
    Akoumianakis, I.
    Akawi, N.
    Cristina, M.
    Herdman, L.
    Badi, I.
    Kotanidis, C.
    Akbar, N.
    Antonopoulos, A.
    Oikonomou, E.
    Chuaiphichai, S.
    Channon, K.
    Antoniades, C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3872 - 3872
  • [30] The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    John A. Spertus
    Mary C. Birmingham
    Michael Nassif
    C. V. Damaraju
    Antonio Abbate
    Javed Butler
    David E. Lanfear
    Ildiko Lingvay
    Mikhail N. Kosiborod
    James L. Januzzi
    Nature Medicine, 2022, 28 : 809 - 813
12345